Skip to main navigation Skip to search Skip to main content

Editorial Perspective: How should child psychologists and psychiatrists interpret FDA device approval? Caveat emptor

  • Martijn Arns*
  • , Sandra K. Loo
  • , M. Barry Sterman
  • , Hartmut Heinrich
  • , Jonna Kuntsi
  • , Philip Asherson
  • , Tobias Banaschewski
  • , Daniel Brandeis
  • *Corresponding author for this work
  • kbo-Heckscher-Klinikum
  • neuroCare Group, Munich, Germany
  • Research Institute Brainclinics, Nijmegen, the Netherlands
  • Department of Psychiatry and Biobehavioral Sciences, Semel Institute for Neuroscience, University of California, Los Angeles, CA, USA
  • Department of Child & Adolescent Mental Health, University Hospital of Erlangen, Erlangen, Germany
  • MRC Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, Kings College London, London, UK
  • Department of Child and Adolescent Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim/Heidelberg University, Mannheim, Germany
  • Department of Child and Adolescent Psychiatry, University of Zurich, Zurich, Switzerland
  • Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland
  • Neuroscience Center Zurich, University of Zurich and ETH Zurich, Zurich, Switzerland

Research output: Contribution to journalReview articlepeer-review

Original languageEnglish
Pages (from-to)656-658
Number of pages3
JournalJournal of Child Psychology and Psychiatry and Allied Disciplines
Volume57
Issue number5
DOIs
Publication statusPublished - 1 May 2016

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Attention deficit hyperactivity disorder
  • diagnostic test
  • electroencephalogram
  • Electroencephalogram-Based Attention Deficit Hyperactivity Disorder Assessment Aid
  • Federal Drug Administration
  • theta-to-beta ratio

Cite this